Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Cubist Seeks Calixa In Antibiotic Push
by Michael McCoy
December 21, 2009
| A version of this story appeared in
Volume 87, Issue 51
Cubist Pharmaceuticals has agreed to acquire privately held Calixa Therapeutics for $92.5 million in cash plus potential payments of up to $310 million, depending on the performance of CXA-201, Calixa’s lead compound. CXA-201 is a combination of CXA-101 and the β-lactamase inhibitor tazobactam. CXA-101 is a novel cephalosporin antibiotic now in Phase II trials. Both CXA-201 and CXA-101 are targeted at serious gram-negative infections. Cubist already markets daptomycin, the first in a new class of antibiotics called lipopeptides.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter